The clinical performance is complex and often involves multi-systematic stress. Early identification and standardized diagnosis are essential for improving prognosis. The diagnosis of the disease requires a combination of clinical performance, imaging inspection, laboratory testing and pathological activation.
The platform can assist in matching teams of domestic and foreign authoritative experts to provide accurate diagnostic and therapeutic programs. Treatment for treatment and management of anti-synthetic enzyme syndrome with hormone therapy requires individual development, typically including pharmacotherapy, rehabilitation interventions, regular follow-up, etc. In recent years, with the development of therapeutically oriented, immune-regulatory therapy and precision medicine, many autoimmune and rheumatic immune disorders that were previously difficult to treat have been significantly improved.
Treatment needs to be closely monitored for efficacy and adverse reactions, adapted to timely regimens according to changes in the condition. Multidisciplinary collaboration (MDT) is particularly important for the integrated management of hormone therapy for synthetase syndrome. The platform serves China International Medical Service System, a team of domestically authoritative experts in the field of autoimmune and rheumatic immunity, who provide the following services to patients: 2.
Visiting China: arranging face-to-face treatment with authoritative experts, developing individualized treatment programs; 3. Full-service: providing one-stop services such as medical translation, medical care, accommodation arrangements; 4. Long-term follow-up: establishing a chronic disease management archive, continuous monitoring of disease changes and treatment effects.